8.9 Race/Ethnicity No consistent differences in the efficacy and safety of SYMLIN have been observed among patients of differing race/ethnicity in SYMLIN clinical trials (n=4257 for Caucasian, n=229 for black, n=337 for Hispanic or Latino, and n=61 for Asian and one or more races) although the smaller sample sizes for non-Caucasians, particularly Asians, limit conclusions
BPC-157 peptide therapy may be suitable for adults seeking relief from musculoskeletal pain or injuries, joint concerns, digestive issues, chronic inflammation, or central nervous system (CNS) disorders.8 11 It could also potentially be used for neuroprotection, nerve regeneration, repairing organ damage from substance overdoses, healing lesions, and more.7 However, its again important to reiterate that nearly all of the above potential benefits of BPC-157 have not been demonstrated in human studies or trials
F.JordanC
DA Meeting News
Understanding bulk pricing helps patients optimise their treatment costs over time